Dinapsoline

Dinapsoline

Dinapsoline
Systematic (IUPAC) name
8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  N
Chemical data
Formula C16H15NO2 
Mol. mass 253.295 g/mol
 N   

Dinapsoline is a drug developed for the treatment of Parkinson's disease,[1] that acts as a selective full agonist at the dopamine D1 receptor.[2][3][4][5]

References

  1. ^ Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics 296 (2): 338–44.  
  2. ^ Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (January 1996). "9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore". Journal of Medicinal Chemistry 39 (2): 549–55.  
  3. ^ Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (August 2002). "(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist". Journal of Medicinal Chemistry 45 (17): 3660–8.  
  4. ^ Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (February 2004). "Synthesis and SAR exploration of dinapsoline analogues". Bioorg. Med. Chem. 12 (4): 715–34.  
  5. ^ Gleason SD, Witkin JM (May 2006). "Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine". Psychopharmacology (Berl.) 186 (1): 25–31.